I want to donate

The Haematology research group at the IDIBGI started in 2007 as an extension of the haematology service at ICO Girona. The group is dedicated to clinical and translational studies in relation to diagnostic, prognostic, and therapeutic processes in hemopathies, the group is made up of haematologists, nurses, biologists and technicians.

Main lines of research
  • Study genetic variants involved in the immune response as survival predictors and graft disease against the host after allogenic transplantation of hematopoietic progenitors.
  • Study biological and pharmacogenomic aspects associated with response to the treatment of acute myeloblastic leukaemia
  • Analysis of genetic polymorphisms as predictors of multiple myeloma progression.
  • Study of genetic polymorphisms involved in evolution and the response to treatment of chronic lymphatic leukaemia.
  • Study of cell populations using flow cytometry for the characterization of hemopathies and detection of residual disease.
Strategic objectives
  • To investigate biological, clinical, and epidemiological aspects of haematological diseases
  • To carry out translational research projects focused on finding prognostic factors or treatment response predictors
  • To carry out clinical research, promoting participation in clinical trials for haematological diseases and participating in national or international cooperative groups.

Oñate G, Bataller A, Garrido A, Hoyos M, Arnan M, Vives S, Coll R, Tormo M, Sampol MA, Escoda L, Salamero O, Garcia A, Bargay J, Aljarilla A, Nomdedeu JF, Esteve J, Sierra J, Pratcorona M

Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1.

Blood Advances, 2022, 6, 882-890

Bataller A, Garrido A, Guijarro F, Oñate G, Diaz-Beya M, Arnan M, Tormo M, Vives S, Queipo DE Llano MP, Coll R, Gallardo D, Vall-Llovera F, Escoda L, García-Guiñon A, Salamero O, Sampol A, Merchan B, Bargay J, Castaño-Díez S, Esteban D, Oliver-Caldes A, Rivero A, Mozas P, López-Guerra M, Pratcorona M, Zamora L, Costa D, Rozman M, Nomdedeu JF, Colomer D, Brunet S, Sierra J, Esteve J

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol.

Blood Advances, 2022, 6, 1193-1206

Ribera J, Granada I, Morgades M, González T, Ciudad J, Such E, Calasanz MJ, Mercadal S, Coll R, González-Campos J, Tormo M, García-Cadenas I, Gil C, Cervera M, Barba P, Costa D, Ayala R, Bermúdez A, Orfao A, Ribera JM

Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols.


Dimopoulos MA, Schjesvold F, Doronin V, Vinogradova O, Quach H, Leleu X, Montes YG, Ramasamy K, Pompa A, Levin MD, Lee C, Mellqvist UH, Fenk R, Demarquette H, Sati H, Vorog A, Labotka R, Du J, Darif M, Kumar S

Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase? 2 trial.


Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Carioli G, Sobas MA, Elli EM, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Gasior Kabat M, Cuevas B, Fox ML, Andrade-Campos MM, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas MA, Bonifacio M, Alvarez-Larran A, Kiladjian JJ, Bolaños Calderón E, Patriarca A, Quiroz Cervantes K, Griessammer M, Garcia-Gutierrez V, Marin Sanchez A, Magro Mazo E, Ruggeri M, Hernandez-Boluda JC, Osorio S, Carreno-Tarragona G, Sagues Serrano M, Kusec R, Navas Elorza B, Angona A, Xicoy Cirici B, Lopez Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, Masternak Kulikowska de Nalecz A, Cavalca F, Borsani O, Betti S, Benajiba L, Bellini M, Curto-Garcia N, Rambaldi A, Vannucchi AM

Second versus first wave of COVID-19 in patients with MPN.

Leukemia, 2022, 36, 897-900

Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.

CANCER, 2022, 128, 2441-2448

Risk prediction of CMV reactivation after allogeneic stem cell transplantation using five non-HLA immunogenetic polymorphisms.

ANNALS OF HEMATOLOGY, 2022, 101, 1567-1576

Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas.

Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 635-642

5'-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics.


Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.

Clinical Lymphoma, Myeloma and Leukemia, 2022, 22
Competitive projects
Codi oficial: PI20/01353 Start date:01/01/2021 Data fi: 31/12/2023 Investigador/a principal: DAVID GALLARDO GIRALT Organisme finançador: INSTITUTO DE SALUD CARLOS III Ajuda: 135,520 €
Job offers


If you are a researcher and you are interested in collaborating with any of our research groups, please fill in this form.
I am interested in
If you are a student or you want to do an internship with any of our research groups, please fill in this form.
I am interested in